MedTrace Logo

Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders

NCT04218981 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-08-21

No results posted yet for this study

Summary

To explore the whole-brain anatomical and functional abnormalities in drug-naive patients with schizophrenia ,drug-naive patients with BD, drug-naive patients with MDD and healthy controls by using a combination of cross-sectional and longitudinal study designs, including a longitudinal study with 8 weeks of drugs treatment. And explore whether there are shared imaging biomarkers between these three common mental disorders.

Conditions

  • Common Mental Disorder

Interventions

DRUG

Antipsychotic drugs

Choose one of these antipsychotics (olanzapine, risperidone; amisulpride) for schizophrenia group

DRUG

Mood stabilizer

Choose lithium or valproate for bipolar disorder group

DRUG

Paroxetine

Patients with major depressive disorder are treated with paroxetine

Sponsors & Collaborators

  • Central South University

    lead OTHER

Principal Investigators

  • Wenbin Guo · The Second Xiangya Hospital, Central South University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-15
Primary Completion
2023-06-25
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04218981 on ClinicalTrials.gov